Subtyping schizophrenia by treatment response: Antipsychotic development and the central role of positive symptoms

Canadian Journal of Psychiatry

Volumn 60, Issue 11, 2015, Pages 515-522

  Lee, Jimmy ^a,b,c   Takeuchi, Hiroyoshi ^c,d   Fervaha, Gagan ^c,e   Sin, Gwen Li ^f   Foussias, George ^c,g   Agid, Ofer ^c,g   Farooq, Saeed ^h,i   Remington, Gary ^c,g  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d KEIO UNIVERSITY   (Japan)

^e UNIVERSITY OF TORONTO   (Canada)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

^g UNIVERSITY OF TORONTO   (Canada)

^h LADY READING HOSPITAL   (Pakistan)

ⁱ STAFFORDSHIRE UNIVERSITY   (United Kingdom)

Author keywords

Antipsychotic; Clozapine; Psychosis; Treatment resistant; Ultraresistant

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

DISEASE CLASSIFICATION; DISEASE DURATION; HUMAN; POSITIVE SYNDROME; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SCHIZOPHRENIA; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; ULTRARESISTANT SCHIZOPHRENIA; CLASSIFICATION; PSYCHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84946840805     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371506001107     Document Type: Review

References (67)

1. Vanelle J. Refractory schizophrenia: historical and currently prevailing criteria and definitions. Eur Psychiatry. 1997;12(Suppl 5):S321-S326.
2. Itil TM, Keskiner A, Fink M. Therapeutic studies in "therapy resistant" schizophrenic patients. Compr Psychiatry. 1966;7(6):488-493.
3. McCreadie RG, MacDonald IM. High dosage haloperidol in chronic schizophrenia. Br J Psychiatry. 1977;131:310-316.
4. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic. a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796.
5. Tuma AH, May PR. And if that doesn't work, what next . . . ? A study of treatment failures in schizophrenia. J Nerv Ment Dis. 1979;167(9):566-571.
6. Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig (DE): Vieweg Verlag; 1988.
7. May PRA, Dencker SJ, Hubbard JW. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. Braunschweig (DE): Vieweg Verlag; 1988. p 22-23.
8. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16(4):551-561.
9. Suzuki T, Remington G, Mulsant BH, et al. Defining treatmentresistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012;197(1-2):1-6.
10. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50(11):898-911.
11. Grunder G, Hippius H, Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8(3):197-202.
12. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-723.
13. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl. 1992(17):41-45.
14. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21-26.
15. Farooq S, Agid O, Foussias G, et al. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull. 2013;39(6):1169-1172.
16. Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci. 2003;28(4):275-284.
17. Biedermann F, Fleischhacker WW. Antipsychotics in the early stage of development. Curr Opin Psychiatry. 2009;22(3):326-330.
18. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17(2):33-37.
19. Keshavan MS, Nasrallah HA, Tandon R. Schizophrenia, "just the facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res. 2011;127(1-3):3-13.
20. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69(6):562-571.
21. Piskulic D, Addington J, Cadenhead KS, et al. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012;196(2-3):220-224.
22. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol. 2009;23(8):957-965.
23. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479.
24. Fervaha G, Agid O, Takeuchi H, et al. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. Eur Neuropsychopharmacol. 2014;24(7):1078-1085.
25. Mouaffak F, Tranulis C, Gourevitch R, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006;29(1):28-33.
26. Marques TR, Levine SZ, Reichenberg A, et al. How antipsychotics impact the different dimensions of schizophrenia: a test of competing hypotheses. Eur Neuropsychopharmacol. 2014;24(8):1279-1288.
27. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50(11):873-883.
28. Wenthur CJ, Lindsley CW. Classics in chemical neuroscience: clozapine. ACS Chem Neurosci. 2013;4(7):1018-1025.
29. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107(3):222-232.
30. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003(416):16-23.
31. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318-2325.
32. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449.
33. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA; 2013.
34. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol Med. 2012;42(3):595-606.
35. Lee J, Takeuchi H, Fervaha G, et al. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. Eur Neuropsychopharmacol. 2014;24(10):1622-1629.
36. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359-369.
37. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70(10):1107-1112.
38. Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481-485.
39. Stroup TS, Gerhard T, Crystal S, et al. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65(2):186-192.
40. Agid O, Foussias G, Singh S, et al. Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55(10):677-684.
41. Remington G, Agid O, Foussias G, et al. Clozapine's role in the treatment of first-episode schizophrenia. Am J Psychiatry. 2013;170(2):146-151.
42. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009(438):7-14.
43. Levine SZ, Rabinowitz J, Case M, et al. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol. 2010;30(4):446-449.
44. Levine SZ, Lurie I, Kohn R, et al. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res. 2011;126(1-3):184-191.
45. Schennach R, Meyer S, Seemuller F, et al. Response trajectories in "real-world" naturalistically treated schizophrenia patients. Schizophr Res. 2012;139(1-3):218-224.
46. Chen L, Johnston JA, Kinon BJ, et al. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial. BMC Psychiatry. 2013;13:320.
47. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11-e13.
48. Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203-1210.
49. Liou YJ, Wang HH, Lee MT, et al. Genome-wide association study of treatment refractory schizophrenia in Han Chinese. PLoS One. 2012;7(3):e33598.
50. Li J, Meltzer HY. A genetic locus in 7p12.2 associated with treatment resistant schizophrenia. Schizophr Res. 2014;159(2-3):333-339.
51. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
52. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
53. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781.
54. Ballon J, Stroup TS. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013;26(2):208-213.
55. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369-373.
56. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72(11):1439-1444.
57. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry. 1989;146(7):905-908.
58. Coward DM, Imperato A, Urwyler S, et al. Biochemical and behavioural properties of clozapine. Psychopharmacology (Berl). 1989;99:S6-S12.
59. Suhara T, Okauchi T, Sudo Y, et al. Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl). 2002;160(1):107-112.
60. Kapur S, McClelland RA, VanderSpek SC, et al. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport. 2002;13(6):831-835.
61. Lee J, Remington G. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia. Am J Psychiatry. 2014;171(1):118-119.
62. Lee J, Takeuchi H, Remington G. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. J Clin Psychopharmacol. 2014;34(4):530-532.
63. Patel MX, Arista IA, Taylor M, et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013;149(1-3):141-148.
64. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(Suppl 12):5-19.
65. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
66. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153(12):1579-1584.
67. Conley RR, Carpenter WT Jr, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry. 1997;154(9):1243-1247.